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A B S T R A C T   
Attention Deficit Hyperactivity Disorder (ADHD) symptoms typically onset early and persist into adulthood for 
many. Robust investigation of symptom continuity and discontinuity requires repeated assessments using the 
same measure, but research is lacking into whether measures used to assess ADHD symptoms in childhood are 
also valid in adulthood. The Strengths and Difficulties Questionnaire (SDQ) is widely used to assess ADHD 
symptoms in children, but little is known about its utility in adulthood. The aim of this study was to assess the 
validity of the SDQ hyperactivity/ADHD subscale to distinguish between cases and non-cases of DSM-5 ADHD at 
age 25 years in a UK population cohort (N = 4121). ADHD diagnosis was derived using the Barkley Adult ADHD 
Rating Scale-IV. Analyses suggested that the self-rated SDQ ADHD subscale had high validity in distinguishing 
ADHD cases/non-cases in young adulthood (area under the curve=0.90, 95% CI=0.87–0.93) and indicated a 
lower cut-point for identifying those who may have an ADHD diagnosis in this age group compared to that 
currently recommended for younger ages. Findings were similar for parent-reports. Our findings suggest that the 
SDQ is suitable for ADHD research across different developmental periods, which will aid the robust investi-
gation of ADHD from childhood to young adulthood.   
1. Introduction 
Attention Deficit Hyperactivity Disorder (ADHD) typically is a 
childhood-onset neurodevelopmental disorder characterized by symp-
toms of inattention and hyperactivity/impulsivity. Symptoms tend to 
decline across childhood and adolescence, but around 65% of in-
dividuals with a childhood diagnosis are estimated to show some level of 
symptom persistence into adulthood (Faraone et al., 2006) and esti-
mates of the prevalence rate of adult ADHD are approximately 2.5% to 
4.4% (Kessler et al., 2006; Simon et al., 2009). ADHD symptoms are 
associated with distress and impairment, including in educational, 
occupational, social and other settings, across childhood, adolescence 
and in adulthood (Asherson et al., 2012; Thapar and Cooper, 2016). 
Given the life-course impacts of ADHD, there is a need to be able to 
assess symptoms across development to monitor and investigate corre-
lates of symptom persistence and desistence. In particular, there is 
growing interest in the transition from childhood and adolescence to 
young adulthood (Ford, 2020) - a period that is associated both with 
changing demands and the transition from child/adolescent mental 
health services (CAMHS) to adult mental health services (AMHS). 
Robust investigation of symptom continuity and discontinuity requires 
repeated assessments using the same measure (Goodman et al., 2007); 
however, there is a lack of research into whether measures commonly 
used to assess ADHD symptoms in childhood and adolescence are also 
Conflict of interest. None. 
* Corresponding author. 
E-mail address: Thapar@Cardiff.ac.uk (A. Thapar).   
1 Joint first author 
Contents lists available at ScienceDirect 
Psychiatry Research 
journal homepage: www.elsevier.com/locate/psychres 
https://doi.org/10.1016/j.psychres.2021.113984 
Received 12 January 2021; Accepted 26 April 2021   
Psychiatry Research 301 (2021) 113984
2
valid assessment tools in adulthood. 
Adult ADHD has generally been assumed to be a continuation of 
childhood ADHD and this is supported by findings that adult ADHD 
symptoms and diagnosis show similar characteristics (e.g. high herita-
bility, associations with other neurodevelopmental problems) when 
accounting for change in measure and informant (Larsson et al., 2014; 
Riglin et al., 2020; Rovira et al., 2020). However, the Diagnostic and 
Statistical Manual of Mental Disorders (5th edition, DSM-5) criteria 
acknowledge some developmental differences by requiring fewer 
symptoms for a diagnosis of ADHD in adulthood compared to earlier in 
life (American Psychiatric Association, 2013). Research also suggests 
some change in the presentation of ADHD symptoms with age, whereby 
inattentive symptoms are more likely to persist whereas 
hyperactive-impulsive symptoms seem to become less common with age 
(Davidson, 2008; Willcutt et al., 2012). The validity of using child/-
adolescent based measures in adulthood cannot therefore be assumed. 
The Strengths and Difficulties Questionnaire (SDQ) hyperactivity/ 
ADHD subscale (Goodman, 1997) is a brief screening tool and has been 
used widely to assess ADHD symptoms in children and adolescents in 
both research and clinical settings across different countries. Self, parent 
and teacher versions of the questionnaire have been validated for chil-
dren and adolescents, with self-reports suitable for children aged 11 
years or older (Goodman, 2001; Goodman et al., 2000; He et al., 2013). 
More recently an adult version of the SDQ has been developed (using 
almost identical wording for the ADHD subscale), which has been found 
to show similar psychometric properties to child/adolescent samples 
(Brann et al., 2018). However, to our knowledge the ADHD subscale of 
the SDQ has yet to be validated against ADHD diagnosis in adulthood. 
The aim of this study was to examine the criterion validity of the SDQ 
as an assessment of ADHD symptoms in young adulthood, by examining 
its ability to discriminate DSM-5 ADHD cases from non-cases at age 25 
years in a UK population cohort. We also explored whether a different 
cut-point to that recommended in childhood and adolescence is required 
to optimize sensitivity and specificity with respect to an adult diagnosis. 
Follow-up analyses included 1) separate analyses for males and females, 
and 2) assessing generalizability across subscales by comparing results 




We analyzed data from the Avon Longitudinal Study of Parents and 
Children (ALSPAC), a well-established prospective, longitudinal birth 
cohort study (Boyd et al., 2013; Fraser et al., 2013; Northstone et al., 
2019) (total possible N = 14,901). Details of this study are provided in 
the Supplementary Material. Ethical approval for the study was obtained 
from the ALSPAC Ethics and Law Committee and the Local Research 
Ethics Committees. Informed consent for the use of data collected was 
obtained from participants following the recommendations of the 
ALSPAC Ethics and Law Committee at the time. Individuals were 
included in our analyses when ADHD diagnosis data were available at 
age 25 years (28% of the total possible sample) (see below): comparisons 
between those with and without diagnosis data are given in Supple-
mentary Table 1. Primary analyses were conducted using self-reports as 
would typically be used in adult mental health services (N = 4121), with 
secondary analyses conducted using parent-reports (N = 4330) (see 
below). 
2.2. Diagnoses 
ADHD diagnosis was assessed at age 25 years using the self-rated 
Barkley Adult ADHD Rating Scale (BAARS-IV) (Barkley, 2011). The 
BAARS-IV is an assessment tool for adult ADHD which includes the 18 
DSM-5 ADHD items and ten domains of impairment (all items scores 
0–3). Diagnoses were generated from the BAARS-IV  based on DSM-5 
criteria (American Psychiatric Association, 2013), using diagnostic 
coding constructed by SSA, KL and LR with advice from clinical psy-
chiatrists OE and RBJ (blinded to the SDQ scores). In-line with recom-
mendations, ADHD symptoms were defined to be clinically significant if 
endorsed as occurring ‘often’ or ‘very often’ (Barkley, 2011). In line with 
DSM-5, diagnostic coding defined ADHD diagnosis as the presence of 
five or more symptoms of inattention or of hyperactivity/impulsivity, 
symptom onset prior to age 12 years (assessed retrospectively also using 
the BAARS-IV), and current symptoms to be accompanied by impair-
ment in social, academic, or occupational functioning (see Supplemen-
tary Table 2) (American Psychiatric Association, 2013). 
2.3. Strengths and Difficulties Questionnaire (SDQ) 
Participants also completed the self-rated age 18+ version of the 
SDQ which includes the five item hyperactivity/ADHD subscale 
(Goodman, 1997) (range 0–10) at age 25 years. The ADHD subscale is 
well-validated in child and adolescent samples, for which the recom-
mended cut-point for “high” symptoms (top 10% of the general popu-
lation) is ≥7, with scores of 0–5 categorized as close to average (Green 
et al., 2005). In line with recommendations (www.sdqinfo.org) total 
ADHD subscale scores were derived using mean imputation for those 
with (≤2) of SDQ items missing. Follow-up analyses investigated the 
other SDQ subscales of emotional problems, conduct problems, peer 
problems and prosocial behavior (each subscale has five items, range 
0–10). The SDQ can be downloaded from https://www.sdqinfo.org/. 
2.4. Analyses 
Data were analyzed using Stata version 14. Receiver Operating 
Characteristic (ROC) curve analyses were used to examine the ability of 
the SDQ to distinguish between cases and non-cases of ADHD classified 
using the BAARS-IV. A ROC curve was plotted (sensitivity vs 1-speci-
ficity) and the area under the curve (AUC) estimated. Stata’s cvauroc 
function (Luque-Fernandez et al., 2019) was used to minimize over-
fitting by implementing a 10-fold cross-validation and bootstrapping 
cross-validated AUC values to obtain bias-adjusted confidence intervals. 
The AUC assesses the diagnostic efficiency of the SDQ subscale in rela-
tion to meeting ADHD diagnostic criteria, whereby 0.5 indicates per-
formance at chance level and 1.0 indicates perfect detection. Values <
0.7 are generally considered low and those >0.9 excellent (Swets, 1988). 
Sensitivity reflects the ability to correctly identify all those with a 
diagnosis (true positives) whereas specificity reflects the ability to 
correctly identify all those without a diagnosis (true negatives). Opti-
mum cut-points for ADHD diagnosis were selected as those that best 
balanced sensitivity and specificity, i.e. assuming that false positives and 
false negatives are equally undesirable, according to maximal Youden 
Index (sensitivity + specificity – 1) (Youden, 1950). Given that previous 
work recommending cut-points in child and adolescent samples were 
based on identifying the top 10% of the population (Goodman, 1997; 
Green et al., 2005), we also explored which cut-points would capture 
10% of our sample. Positive predictive values (PPV) and negative pre-
dictive values (NPV) were calculated for proposed cut-points, which 
reflect the probability that those exceeding the cut-point have a diag-
nosis and the probability that those not meeting the cut-point do not 
have a diagnosis, respectively. 
Follow-up analyses were conducted (i) separately for males and fe-
males, using Stata’s roccomp function (Cleves, 2002) to compare AUC 
values by sex, and (ii) using the other SDQ subscales to distinguish be-
tween cases and non-cases of ADHD. Secondary analyses were con-
ducted using parent-reports instead of self-reports. As parents have been 
observed to be important informants for ADHD symptoms even in early 
adulthood (Barkley et al., 2002), we tested the validity of the 
parent-rated SDQ against parent-reported diagnosis (see Supplementary 
Material). 
L. Riglin et al.                                                                                                                                                                                                                                   
Psychiatry Research 301 (2021) 113984
3
3. Results 
3.1. ADHD symptom scores using SDQ 
The overall mean self-rated SDQ hyperactivity/ADHD subscale score 
at age 25 years was 3.09 (SD=2.11) with a Cronbach’s alpha of 0.67, 
suggesting acceptable levels of internal consistency. As has been re-
ported elsewhere (Riglin et al., 2020), the mean SDQ hyperactivity score 
was higher in males than in females (mean difference=0.36, 95% 
CI=0.22–0.50, p = 2.3×10–07). Mean scores for those who met DSM-5 
ADHD diagnostic criteria were 6.70 (SD=1.92) compared to 2.98 
(SD=2.02) for those who did not meet diagnostic criteria (mean differ-
ence=3.72, 95% CI=3.36–4.08, p = 3×10–85). 
3.2. DSM-5 diagnosis of ADHD 
Of those with available data, 2.9% met DSM-5 diagnostic criteria for 
ADHD at age 25 years (see Supplementary Table 2). At age 25 years, 
male sex was not associated with an increased likelihood of meeting 
ADHD criteria (3.0% in females and 2.9% in males: OR=0.97, 95% 
CI=0.66–1.43, p = 0.89). 
3.3. Receiver Operating Characteristic (ROC) curve analyses 
ROC curve analyses suggested the SDQ ADHD subscale has high 
validity in distinguishing ADHD cases from non-cases (AUC=0.90, 95% 
CI=0.87–0.93), as shown in Fig. 1. Sensitivity and specificity values for 
all possible SDQ ADHD subscale cut-points are shown in Table 1. 
3.4. Optimum cut-points 
The optimum cut-point for distinguishing ADHD cases from non- 
cases was ≥5, which showed high validity in correctly identifying 
those meeting diagnostic criteria (i.e. true positives: sensitivity=89.3%) 
and good validity in correctly identifying those who did not meet 
diagnostic criteria (i.e. true negatives: specificity=76.7%). This cut- 
point captured 25.3% of the sample and was associated with a very 
high probability that those not meeting the cut-point did not meet 
diagnostic criteria (NPV=99.6%) but a lower probability that those 
exceeding the cut-point met diagnostic criteria (PPV=10.4%). 
In line with previous work in younger samples (Goodman, 1997; 
Green et al., 2005) we also inspected the cut-points which identified the 
top 10% of the sample: this was ≥6 (sensitivity=76.0% and specific-
ity=88.7%), which again was associated with a very high but slightly 
attenuated probability that those not meeting the cut-point did not meet 
diagnostic criteria (NPV=99.1%) but a slightly higher probability those 
exceeding the cut-point met diagnostic criteria (PPV=16.9%). The 2×2 
tables for SDQ cut-point by whether or not individuals met diagnostic 
criteria along with sensitivity, specificity, PPV and NPV for both SDQ 
cut-points (≥5 and ≥6) are shown in Supplementary Table 3. 
3.5. Analyses for males and females separately 
When examining males and females separately, ROC curve analyses 
still indicated high validity in distinguishing ADHD cases from non-cases 
(males AUC=0.90, 95% CI=0.86–0.94; females AUC=0.90, 95% 
CI=0.87–0.94) with similar AUC values across sex (χ2(1)=0.02, p =
0.89). Sensitivity and specificity values for all possible SDQ subscale cut- 
points are shown in Table 2. The identified (whole-sample) cut-point of 
≥5 captured 30.2% of males (NPV=99.6%, PPV=8.6%) and 22.7% of 
females (NPV=99.6%, PPV=11.6%) in our sample. 
3.6. Other SDQ subscales 
Analyses examining the other SDQ subscales found lower validity in 
distinguishing ADHD cases from non-cases; as shown in Table 3, AUC 
values ranged from 0.58 to 0.75 for the prosocial, conduct problems, 
peer problems and emotional problems subscales. 
3.7. Secondary analyses using parent-reports 
Analyses using parent-reported data found that the parent-reported 
SDQ was also able to accurately identify ADHD diagnosis (see Supple-
mentary Material): AUC=0.97 (95% CI=0.92–0.98) but with a lower 
optimum cut-point of ≥4, capturing 13.2% of the sample. 
4. Discussion 
This study aimed to examine the validity of the SDQ as an assessment 
of ADHD symptoms at age 25 years in a UK population cohort. We found 
the hyperactivity/ADHD subscale to have high validity in distinguishing 
those meeting ADHD diagnostic criteria from those who did not. This 
suggests that the SDQ subscale, which is widely used in child and 
adolescent populations, is also suitable for use in young adults. 
Our finding of excellent validity of the self-rated SDQ for measuring 
ADHD in young adulthood (AUC=0.90) is similar if not somewhat 
higher than previous work in children and adolescents (using self- and 
parent-reports) (Algorta et al., 2016; Goodman et al., 2003), including 
previous work in the present sample at age 17 years (AUC=0.89) using 
parent-reports (Caye et al., 2019). In general, despite the trend that 
hyperactive-impulsive symptoms are likely to decline whilst inattentive 
symptoms persist with age (Davidson, 2008; Willcutt et al., 2012), the 
SDQ subscale - which includes three hyperactive-impulsive and two 
inattentive symptoms - shows high validity across childhood, adoles-
cence and into young adulthood. This suggests that while the presen-
tation of symptoms may change with age, the SDQ items capture a 
similar construct. Indeed, previous work in a smaller high-risk sample 
Fig. 1. Receiver Operating Characteristic (ROC) curves for SDQ using ADHD 
diagnosis as criterion. 
Table 1 
Sensitivity and specificity for SDQ hyperactivity/ADHD cut-points compared 
against ADHD diagnosis.  
Cut-point Sensitivity (95% CI) Specificity (95% CI) 
≥ 1 99.2% (95.5–100.0) 11.9% (10.9–12.9) 
≥ 2 99.2% (95.5–100.0) 26.7% (25.3–28.1) 
≥ 3 98.4% (94.2–99.8) 43.5% (41.9–45.0) 
≥ 4 94.2% (88.4–97.6) 61.9% (60.3–63.4) 
≥ 5 89.3% (82.3–94.2) 76.7% (75.3–78.0) 
≥ 6 76.0% (67.4–83.3) 88.7% (87.7–89.7) 
≥ 7 51.2% (42.0–60.4) 94.6% (93.9–95.3) 
≥ 8 37.2% (28.6–46.4) 98.2% (97.7–98.6) 
≥ 9 20.7% (13.8–29.0) 99.6% (99.4–99.8) 
≥ 10 5.0% (1.84 –10.5) 100.0% (99.8–100.0)  
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found the SDQ to have similar psychometric properties (e.g. inter-scale 
correlations, internal consistency, and inter-rater agreement) in adults 
compared with adolescents (Brann et al., 2018). 
We also investigated whether different cut-points are required to 
capture clinically relevant symptoms in young adulthood compared to 
younger ages. Current recommendations based on identifying the top 
10% of the population suggest that in childhood and adolescence, self- 
rated scores of ≥7 capture those with high symptoms, with scores of 
0–5 capturing those close to average (Goodman, 1997; Green et al., 
2005). At age 25 years, our results suggest that lower cut-points are 
needed to capture clinically relevant symptoms, with scores of ≥5 
achieving the best balance between sensitivity and specificity in iden-
tifying those meeting ADHD diagnostic criteria and a cut-point of ≥6 
capturing 10% of our sample. These lower thresholds likely reflect the 
generally lower levels of ADHD symptoms in adulthood and is consistent 
with diagnostic criteria that require fewer symptoms to be present for an 
adult diagnosis to be made (American Psychiatric Association, 2013). 
While these cut-points performed well in identifying those meeting 
diagnostic criteria, this short screening tool captured a broader group of 
individuals, with the cut-point of ≥5 capturing 25% of the sample. For 
those aiming to identify a smaller proportion of their research samples, it 
may be preferential to select the top 10% (requiring a cut-point of ≥6 in 
this sample). Replication of these cut-points in different samples is an 
important area for future research. 
The selection of appropriate cut-points depends on the aim and 
rationale for using the instrument. We selected cut-points based on the 
premise that false positives and false negatives were equally undesirable 
(Youden, 1950), which is most likely appropriate for a one-stage 
approach in research settings to define a group most likely to have a 
diagnosis. However, for use in high-risk samples or as a clinical 
screening measure, possible cases would be followed up with further 
clinical assessment in a two-stage approach. In these circumstances, an 
increased number of false positives may be considered acceptable 
(Goodman, 1997) and lower cut-points that favor sensitivity may be 
preferable. In contrast, higher cut-points that favor specificity would be 
more appropriate for measures that are used for diagnostic purposes 
(Silva et al., 2015). The selection of cut points can also depend on sample 
characteristics such as age and sex. Our study suggests the need for a 
lower cut-point in young adulthood to capture ADHD in young adult-
hood than in childhood/adolescence, but we found little evidence of sex 
differences in the ability of the SDQ to assess young adult ADHD, in line 
with previous work in children and adolescents (Algorta et al., 2016). 
Finally, we found the ADHD subscale of the SDQ to show higher validity 
in distinguishing between cases and non-cases of ADHD compared to the 
other SDQ subscales (emotional, conduct, peer, prosocial), which sup-
port the specificity of this subscale. 
While our primary analyses focused on self-reports, we conducted 
secondary analyses using parent-reports (of both the SDQ and to define 
diagnosis). While adult mental health services may not typically involve 
parents, research studies often utilize parent ratings at earlier ages, 
making the validity of the parent-rated SDQ to assess ADHD in young 
adulthood important for researchers interested in assessing continuity 
and discontinuity, which ideally requires repeated assessments using the 
same measure and informant (Goodman et al., 2007). We found 
parent-ratings using the young adult SDQ to also show high validity and 
– consistent with our primary analyses using self-reports – results sug-
gested that lower cut-points are needed to capture clinically relevant 
symptoms (≥4 in young adulthood compared to ≥8 in 
childhood/adolescence.) 
The validity of parent ratings of their young adult offspring’s ADHD 
symptoms is consistent with recent work in this sample which found 
parent SDQ ratings of ADHD show similar genetic and neuro-
developmental correlates at age 25 as in childhood, suggesting that 
these reports capture a similar construct across development (Riglin 
et al., 2020) and implying that parents may still provide valuable insight 
into their offspring’s symptoms at 25 years. 
Our study has a number of strengths, including the use of a large 
population sample and the investigation of a measure widely used in 
childhood and adolescence, which will enable continuity in future 
investigation of ADHD across different developmental periods. Howev-
er, findings should also be considered in light of limitations, including 
non-random attrition which means those included in this sample will not 
be fully representative of the broader population, as those with elevated 
risk of psychopathology are more likely to have dropped out of this 
birth-cohort by the time data were collected at age 25 years (Martin 
et al., 2016; Taylor et al., 2018). This is particularly relevant to sample 
specific cut-points (i.e. capturing the top 10%) which will likely be lower 
than would be found in the general population. We were also reliant on 
questionnaire rather than direct interview data to generate ADHD di-
agnoses, although this is a widely used tool which covers all diagnostic 
criteria, including impairment and age-at-onset (Barkley, 2011). Finally, 
it is not clear the extent to which findings from this community sample 
are applicable to high-risk or clinical samples. 
In conclusion, we found the widely-used and freely-available SDQ, 
used in children and adolescents, to be a valid measure for assessing 
ADHD symptoms in young adults (at age 25 years). We identified a 
different, lower cut-point to help more accurately identify those who 
may have an ADHD diagnosis in this age group. Our findings suggest 
that the SDQ is suitable for ADHD research across different develop-
mental periods, which will aid the robust investigation of ADHD from 
childhood to young adulthood. 
Table 2 
Sensitivity and specificity for SDQ hyperactivity/ADHD cut-points compared against ADHD diagnosis for males and females separately.   
Males Females 
Cut-point Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) 
≥ 1 100.0% (91.2–100.0) 10.4% (8.8–12.2) 98.8% (93.3–100.0) 12.7% (11.4 - 14.0) 
≥ 2 100.0% (91.2–100.0) 23.9% (21.6–26.2) 98.8% (93.3–100.0) 28.2% (26.4–29.9) 
≥ 3 100.0% (91.2–100.0) 39.4% (36.8–42.0) 97.5% (91.4–99.7) 45.6% (43.6–47.5) 
≥ 4 97.5% (86.8–99.9) 56.1% (53.4–58.8) 92.6% (84.6–97.2) 64.8% (63.0–66.6) 
≥ 5 90.0% (76.3–97.2) 71.6% (69.1–73.9) 88.9% (80.0–94.8) 79.3% (79.7–80.8) 
≥ 6 77.5% (61.5–89.2) 85.8% (83.8–87.6) 75.3% (64.5–84.2) 90.2% (89.0–91.3) 
≥ 7 57.5% (40.9–73.0) 92.8% (91.3–94.1) 48.2% (36.9–59.5) 95.6% (94.7–96.3) 
≥ 8 35.0% (20.6–51.7) 98.0% (97.1–98.7) 38.3% (27.7–49.7) 98.3% (97.7–98.8) 
≥ 9 20.0% (9.1–35.6) 99.6% (99.0–99.8) 21.0% (12.7–31.5) 99.7% (99.4–99.8) 
≥ 10 5.0% (0.6–16.9) 99.9% (99.6–100.0) 4.9% (1.4 − 12.2) 100.0% (99.8 − 100.0)  
Table 3 
Area under the curve (AUC) for Strengths and Difficulties Questionnaire 
(SDQ) subscales compared against ADHD diagnosis.   
AUC (95% CI) 
Hyperactivity/ADHD subscale 0.90 (0.87–0.93) 
Emotional problems subscale 0.75 (0.70–0.79) 
Conduct problems subscale 0.65 (0.56–0.68) 
Peer problems subscale 0.72 (0.65–0.76) 
Prosocial subscale 0.58 (0.49–0.61) 
Mean cross-validated AUC values and bootstrap bias corrected 95% 
confidence intervals. 
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Gholizadeh, S., Hodgkins, P., 2012. Under diagnosis of adult ADHD: cultural 
influences and societal burden. J. Atten. Disord. 16 (5_suppl), 20S–38S. 
Barkley, R.A., 2011. Barkley Adult ADHD Rating Scale-IV (BAARS-IV). Guilford Press. 
Barkley, R.A., Fischer, M., Smallish, L., Fletcher, K., 2002. The persistence of attention- 
deficit/hyperactivity disorder into young adulthood as a function of reporting source 
and definition of disorder. J. Abnorm. Psychol. 111 (2), 279–289. 
Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., 
Ness, A., Ring, S., Davey Smith, G., 2013. Cohort profile: the ’children of the 
90s’–the index offspring of the Avon longitudinal study of parents and children. Int. 
J. Epidemiol. 42 (1), 111–127. 
Brann, P., Lethbridge, M.J., Mildred, H., 2018. The young adult strengths and difficulties 
questionnaire (SDQ) in routine clinical practice. Psychiatry Res. 264, 340–345. 
Caye, A., Agnew-Blais, J., Arseneault, L., Gonçalves, H., Kieling, C., Langley, K., 
Menezes, A.M.B., Moffitt, T.E., Passos, I.C., Rocha, T.B., Sibley, M.H., Swanson, J.M., 
Thapar, A., Wehrmeister, F., Rohde, L.A., 2019. A risk calculator to predict adult 
attention-deficit/hyperactivity disorder: generation and external validation in three 
birth cohorts and one clinical sample. Epidemiol. Psychiatr. Sci. 29, e37. 
Cleves, M.A., 2002. From the help desk: comparing areas under receiver operating 
characteristic curves from two or more probit or logit models. Stata J 2 (3), 301–313. 
Davidson, M.A., 2008. Literature review: ADHD in adults:a review of the literature. 
J. Atten. Disord. 11 (6), 628–641. 
Faraone, S.V., Biederman, J., Mick, E., 2006. The age-dependent decline of attention 
deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol. Med. 36 
(2), 159–165. 
Ford, T., 2020. Transitional care for young adults with ADHD: transforming potential 
upheaval into smooth progression. Epidemiol. Psychiatr. Sci. 29, e87. 
Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., 
Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 
2013. Cohort profile: the Avon longitudinal study of parents and children: ALSPAC 
mothers cohort. Int. J. Epidemiol. 42 (1), 97–110. 
Goodman, R., 1997. The Strengths and Difficulties Questionnaire: a research note. 
J. Child Psychol. Psychiatry 38 (5), 581–586. 
Goodman, R., 2001. Psychometric properties of the strengths and difficulties 
questionnaire. J. Am. Acad. Child Adolesc. Psychiatry 40 (11), 1337–1345. 
Goodman, R., Ford, T., Simmons, H., Gatward, R., Meltzer, H., 2000. Using the strengths 
and difficulties questionnaire (SDQ) to screen for child psychiatric disorders in a 
community sample. Br. J. Psychiatry 177, 534–539. 
Goodman, R., Iervolino, A.C., Collishaw, S., Pickles, A., Maughan, B., 2007. Seemingly 
minor changes to a questionnaire can make a big difference to mean scores: a 
cautionary tale. Soc. Psychiatry Psychiatr. Epidemiol. 42 (4), 322–327. 
Goodman, R., Meltzer, H., Bailey, V., 2003. The strengths and difficulties questionnaire: 
a pilot study on the validity of the self-report version. Int. Rev. Psychiatry 15 (1–2), 
173–177. 
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